

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



撥康視云™

Cloudbreak Pharma

CLOUDBREAK PHARMA INC.

撥康視雲製藥有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2592)

**(1) RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR;
(2) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR; AND
(3) CHANGE OF COMPOSITION OF BOARD COMMITTEES**

The board (the “**Board**”) of directors (the “**Directors**”) of Cloudbreak Pharma Inc. (the “**Company**”; together with its subsidiaries, the “**Group**”) hereby announces that:

1. Mr. LAI Hin Wing Henry Stephen (賴顯榮) (“**Mr. Lai**”) has tendered his resignation as an independent non-executive Director (“**INED**”), the chairman of the nomination committee of the Company (the “**Nomination Committee**”), a member of the audit committee of the Company (the “**Audit Committee**”) and a member of the remuneration committee of the Company (the “**Remuneration Committee**”; together with the Audit Committee and the Nomination Committee, the “**Board Committees**”) with effect from 1 December 2025;
2. Mr. LEE Alex Jao Jang (李朝昌) (“**Mr. Lee**”) will be appointed as an INED, a member of the Audit Committee and a member of the Nomination Committee with effect from 1 December 2025; and
3. Dr. NI Jinsong (“**Dr. Ni**”), the chairman of the Board (the “**Board Chairman**”), an executive Director (“**ED**”) and chief executive officer of the Company (“**CEO**”), will be appointed as the chairman of the Nomination Committee with effect from 1 December 2025.

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR

Board hereby announces that Mr. Lai has tendered his resignation as an INED, the chairman of the Nomination Committee, a member of the Audit Committee and a member of the Remuneration Committee with effect from 1 December 2025 in order to devote more time to his other business commitments.

Mr. Lai has confirmed that: (i) he has no disagreement with the Board; and (ii) there is no other matter that needs to be brought to the attention of the shareholders of the Company in respect of his said resignation.

The Board would like to express its gratitude to Mr. Lai for his services to the Company during his tenure.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board is pleased to announce that Mr. Lee will be appointed as an INED, a member of the Audit Committee and a member of the Nomination Committee with effect from 1 December 2025.

The biographical details of Mr. Lee are as follows:

Mr. Lee, aged 46, obtained his bachelor's degree in commerce, majoring in finance and his bachelor's degree in law from the University of New South Wales, Australia, in April 2000 and October 2001, respectively. Mr. Lee is a qualified solicitor in Hong Kong, New South Wales, Australia and England and Wales. Mr. Lee has over 20 years of experience in the legal industry and is currently a partner of Jun He Law Offices in Hong Kong. He specialises in the area of banking and finance, regularly advising major banks in the People's Republic of China and international banks, as well as state-owned enterprises and companies listed on the Stock Exchange in relation to financing matters, including but not limited to syndicated loans, structured finance and debt placements.

Mr. Lee has entered into a letter of appointment (the “**Letter of Appointment**”) with the Company in relation to his appointment as an INED for an initial term of three (3) years commencing from 1 December 2025, subject to retirement by rotation and re-election at annual general meetings of the Company in accordance with the articles of association of the Company. Mr. Lee's appointment may be terminated by not less than thirty (30) days' prior notice in writing served by either party and expiring not earlier than the date of the next annual general meeting of the Company within one (1) year following his appointment. Mr. Lee is entitled to a remuneration of US\$25,000 per annum (or a pro rata amount for any incomplete year), payable in arrears on or before the end of the last month of each financial year of the Company or upon the termination of his appointment, as applicable. Save as aforesaid, Mr. Lee is not entitled to any other remuneration under the Letter of Appointment. The aforesaid remuneration of Mr. Lee has been determined having regard to his experience, duties and responsibilities, the recommendation of the Remuneration Committee as well as the prevailing market conditions, and will be reviewed by the Remuneration Committee and the Board on an annual basis having regard to the operating results of the Group and Mr. Lee's performance of his duties.

Save as disclosed hereinabove, as at the date of this announcement, Mr. Lee: (i) does not have any interests or short positions and is not deemed to have any interests or short positions in any shares, underlying shares or debentures of the Company or its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (ii) does not hold any other position within the Company or any other company within the Group; (iii) does not at present and did not in the last three (3) years immediately preceding the date of his appointment

hold any directorship in any other public companies the securities of which are listed on the Stock Exchange or any other securities market whether within or outside Hong Kong; and (iv) does not have any relationship with any other Directors, members of senior management, substantial shareholders or controlling shareholders (each as defined in the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”)) of the Company.

Mr. Lee has confirmed to the Company his independence as regards each of the factors referred to in Rule 3.13 of the Listing Rules and that: (i) he does not have any past or present financial or other interests in the business of the Group or any connection with any of the core connected persons (as defined in the Listing Rules) of the Company; and (ii) there are no other factors which affect or may affect his independence at the time of his appointment.

Save as disclosed hereinabove, there are no other matters that need to be brought to the attention of shareholders of the Company or the Stock Exchange in relation to the appointment of Mr. Lee and there is no other information required to be disclosed pursuant to the requirements under Rule 13.51(2) of the Listing Rules.

The Board would like to take this opportunity to express its warmest welcome to Mr. Lee for his appointment as an INED of the Company.

CHANGE OF COMPOSITION OF BOARD COMMITTEES

In addition to the appointment of Mr. Lee as a member of the Audit Committee and a member of the Nomination Committee as mentioned hereinabove, Dr. Ni, who currently serves as the Board Chairman, an ED and the CEO, will be appointed as the chairman of the Nomination Committee with effect from 1 December 2025.

The biographical details of Dr. Ni are set out in the prospectus issued by the Company on 24 June 2025 (the “**Prospectus**”). To best of the knowledge, information and belief of the Board, as at the date of this announcement, there have been no material changes to the biographical details of Dr. Ni as stated in the Prospectus.

Immediately following the above-mentioned changes to the composition of the Board Committees, with effect from 1 December 2025:

- (a) the Audit Committee will comprise Mr. MA Yiu Ho Peter (馬遙豪) (“**Mr. Ma**”) as the chairman and Dr. LI Jun Zhi (“**Dr. Li**”), Ms. NIE Sijiang (聶四江) (“**Ms. Nie**”) and Mr. Lee as members;
- (b) the Remuneration Committee will comprise Ms. Nie as chairlady, Dr. Li and Mr. Ma as members;
and

- (c) the Nomination Committee will comprise Dr. Ni as chairman and Dr. Li, Ms. Nie, Mr. Ma and Mr. Lee as members.

By order of the Board
Cloudbreak Pharma Inc.

Dr. NI Jinsong

Chairman of the Board, Executive Director and Chief Executive Officer

Hong Kong, 27 November 2025

As at the date of this announcement, the board of directors of the Company comprises: (i) Dr. Ni Jinsong, Mr. Dinh Son Van and Dr. Yang Rong as executive directors; (ii) Dr. Li Jun Zhi, Mr. Cao Xu and Mr. Xia Zhidong as non-executive directors; and (iii) Mr. Lai Hin Wing Henry Stephen, Ms. Nie Sijiang and Mr. Ma Yiu Ho Peter as independent non-executive directors.

* *For identification purpose only*